3 Stocks Advancing The Drugs Industry
Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.
Two out of the three major indices are trading lower today with the
Dow Jones Industrial Average
(
^DJI
) trading down 41 points (-0.2%) at 18,075 as of Tuesday, March 24, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,371 issues advancing vs. 1,586 declining with 175 unchanged.
The Drugs industry currently sits up 1.1% versus the S&P 500, which is down 0.2%. Top gainers within the industry include
(
), up 1.9%, and
(
), up 0.6%. On the negative front, top decliners within the industry include
(
), down 0.8%,
(
), down 0.7% and
(
), down 0.5%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $0.73 (1.5%) to $50.14 on heavy volume. Thus far, 2.0 million shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $50.11-$50.52 after having opened the day at $50.17 as compared to the previous trading day's close of $49.41.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $131.3 billion and is part of the health care sector. Shares are up 16.8% year-to-date as of the close of trading on Monday. Currently there are 2 analysts who rate Novo Nordisk A/S a buy, no analysts rate it a sell, and 1 rates it a hold.
TheStreet Ratings rates
Novo Nordisk A/S
as a
. The company's strengths can be seen in multiple areas, such as its notable return on equity, expanding profit margins, increase in stock price during the past year and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full
Novo Nordisk A/S Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
Valeant Pharmaceuticals International
(
) is up $1.31 (0.6%) to $204.98 on light volume. Thus far, 557,834 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 3.2 million shares. The stock has ranged in price between $203.38-$206.00 after having opened the day at $204.23 as compared to the previous trading day's close of $203.67.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $68.7 billion and is part of the health care sector. Shares are up 42.3% year-to-date as of the close of trading on Monday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
Valeant Pharmaceuticals International
as a
. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full
Valeant Pharmaceuticals International Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
(
) is up $0.68 (0.6%) to $123.62 on average volume. Thus far, 2.3 million shares of Celgene exchanged hands as compared to its average daily volume of 5.5 million shares. The stock has ranged in price between $122.22-$124.50 after having opened the day at $123.23 as compared to the previous trading day's close of $122.94.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases in the United States and Internationally. Celgene has a market cap of $102.9 billion and is part of the health care sector. Shares are up 9.9% year-to-date as of the close of trading on Monday. Currently there are 16 analysts who rate Celgene a buy, no analysts rate it a sell, and 4 rate it a hold.
TheStreet Ratings rates
Celgene
as a
. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).
null